A distinct genotype (designated Dd2-type profile) consisting of 12 point mutations and 3 repetitive regions of the CG2 gene, a candidate gene for chloroquine resistance, has been associated with in vitro resistance in laboratory-adapted strains of Plasmodium falciparum. The DNA sequence of clinical isolates, characterized by in vitro and in vivo tests, was analyzed to evaluate whether the genotype corresponds to the phenotype in naturally occurring parasites. Eight of 11 chloroquine-resistant isolates had the Dd2 genotype. One resistant isolate (by in vitro assay) with a sensitive CG2 genotype was sensitive in vivo. Two resistant isolates and 6 sensitive isolates were multiple infections with mixed alleles. No typical CG2 genotype was found corresponding to the chloroquine-sensitive isolates. These results suggest a strong association between the drug-resistant and CG2 genotypes and support the hypothesis that the CG2 gene may be implicated in chloroquine resistance.
with the process of hemoglobin degradation, either through an interaction with hematin or by direct inhibition of vacuolar enzymes [4, 5] . The inhibition of hemoglobin digestion results in the deprivation of amino acids derived from hemoglobin, which are necessary for the parasite's metabolism, and/or an accumulation of toxic free hematin that is not sequestered into hemozoin or malarial pigment, leading to the parasite's death. Chloroquine-resistant parasites can be distinguished from chloroquine-sensitive parasites on the basis of the lower accumulation of the drug in infected erythrocytes [6] . Several underlying processes-rapid efflux mediated by a multidrug-resistant (MDR) pump, reduced influx of and lower affinity for chloroquine associated with Na ϩ /H ϩ antiporter, and a defective proton pump that regulates the pH of the digestive vacuole-have been proposed to explain the differential accumulation of chloroquine in malaria-infected erythrocytes, but the precise biochemical basis for chloroquine resistance has not been elucidated [7] [8] [9] .
Full understanding of the mechanisms of action and resistance requires the identification and characterization of the chloroquine resistance gene. Two candidate gene families have been proposed. The first candidate gene, denoted PFMDR-1 (P. falciparum MDR 1), was located in chromosome 5 and was cloned on the basis of sequence homologies with genes belonging to the ATP-binding cassette (ABC) family [10, 11] . These genes are present in prokaryotes and eukaryotes, and their expression products are involved in the transport process of various substrates, including antitumor agents. Although initial studies suggested a correlation between a single-point mutation (AsnrTyr substitution at position 86) or gene amplification of PFMDR-1 and chloroquine resistance, subsequent studies produced contradictory conclusions on its possible role in the development of chloroquine resistance [12] [13] [14] [15] . A second candidate gene for chloroquine resistance, denoted CG2, was identified recently in chromosome 7 [16] . By use of a panel of laboratory strains of P. falciparum, a distinct profile of CG2, characterized by 12 nonsilent point mutations and 3 polymorphic repeat regions, was shown to be associated with in vitro chloroquine resistance. There was no characteristic genetic profile featuring the chloroquine-sensitive strains. Other genes may also be directly or indirectly associated with chloroquine resistance.
It is not known whether the mutations and polymorphic regions of the CG2 gene are found in naturally occurring parasites and are predictive of therapeutic failure of chloroquine treatment. In the present study, we analyzed the CG2 sequences of recent P. falciparum clinical isolates from Yaoundé, Cameroon (Central Africa), where the epidemiology of drug resistance has been monitored for more than a decade. All parasite DNA samples were analyzed by DNA sequencing to determine the nucleotides (nts) at 12 key positions and the number of repeat units in the polymorphic regions that were shown to differ between chloroquine-sensitive and chloroquine-resistant reference clones by Su et al. [16] . The drug sensitivity/resistance phenotype of fresh clinical isolates was determined by in vitro and in vivo responses to chloroquine and was compared with the genotype defined by CG2 polymorphisms.
Materials and Methods
DNA extraction from blood samples. Blood samples (10 mL each) were collected by venipuncture before treatment from Cameroonian patients who met the following inclusion criteria: age у5 years, fever, monoinfection with P. falciparum (parasite density 15000 asexual parasites/mL of blood), and no recent history of selfmedication with antimalarial drugs. A 1.5-to 2.0-mL aliquot of red blood cell pellet was used to extract parasite DNA. Infected erythrocytes were suspended in 15 mL of ice-cold NET buffer (150 mM NaCl, 10 mM EDTA, 50 mM Tris at pH 7.5) and lysed with 0.015% saponin. The lysate was centrifuged at 2000 g for 10 min, and the pellet was transferred to a 1.5-mL microfuge tube and suspended in 500 mL of NET buffer. The mixture was treated with 1% N-laurylsarcosine and RNAse A (100 mg/mL) at 37ЊC for 1 h and with proteinase K (200 mg/mL) at 50ЊC for 1 h. Parasite DNA was extracted 3 times in equilibrated phenol at pH 8, phenol-chloroform-isoamyl alcohol (v/v/v 25 : 24 : 1), and chloroform-isoamyl alcohol (v/v 24 : 1) and was precipitated by the addition of 0.3 M sodium acetate and cold absolute ethanol. The extracted DNA was dried and was resuspended in TE buffer (10 mM Tris, 1 mM EDTA). The DNA samples were stored at Ϫ20ЊC until use.
Nested polymerase chain reaction amplification of CG2. Because of the limited quantity of genomic parasite DNA available from each patient, we adopted a nested (or seminested) polymerase chain reaction (PCR) strategy to obtain sufficient DNA for sequencing. Two primary amplification reactions were performed to yield 2 overlapping 3.0-and 4.8-kb DNA fragments (∼1 kb overlap) that span almost 80% of the CG2 coding region (8.4 kb), including the regions where polymorphisms occur. The reaction mixture consisted of ∼200-500 ng of genomic DNA (contaminated with human leukocyte DNA), 20 pmol of primer pairs CG-3 5 -GTTATAGTAATTATATAACCTCTCAGGAGG-3 and CG-6R 5 -TTGTAAATCTAGGGCACATTTTTTCTTTTG-3 (for the 3.0-kb fragment; primers corresponding to nt 761-790 and 3732-3703, respectively; HB3 numbering) or CG-5 5 -GGAG-ACACAACTAAAAAGGGAATTGAAAAG-3 and CG-8R 5 -ATTCAATGAGCAATTTATTTCACAGTTTTC-3 (for the 4.8-kb fragment; corresponding to nts 2691-2720 and 7464-7435, respectively), 50 mM KCl, 10 mM Tris at pH 8.3, 2.25 mM MgCl 2 , 500 mM dNTP, and 2.6 U of a mixture containing Taq and Pwo DNA polymerases (Expand Long Template PCR system; Roche Diagnostics, Meylan, France) in a final volume of 50 mL. The thermocycler was programmed as follows: 94ЊC for 2 min for the first cycle and 1 min in subsequent cycles, 60ЊC for 5 min for the first cycle and 2 min in subsequent cycles, and 68ЊC for 10 min in all cycles, with an additional extension step of 68ЊC for 15 min after the completion of 30 cycles. The amplification product was diluted to 1 : 100-1 : 1000 for further amplification reactions.
A secondary (seminested or nested) amplification reaction was done with the following reaction mixture: diluted primary amplification product (2-4 mL), 15 pmol of internal primer pairs, 25 mM KCl, 5 mM (NH 4 ) 2 SO 4 , 10 mM Tris at pH 8. (4942-4971), CG-15R, 5 -CATTTTTATTTTTTGTTTTATTTAAATCGG-3 (5476-5447), and CG19R, 5 -TGAATACTCCTCCCCACA-CACCTCACCATC-3 (7395-7366). The PCR program was modified to 94ЊC for 2 min for the first cycle and 30 s in subsequent cycles, 60ЊC for 1 min for the first cycle and 30 s in subsequent cycles, and 72ЊC for 1 min for all cycles, for a total of 30 cycles, followed by a 15-min extension step at 72ЊC.
The amplified DNA fragments were resolved by electrophoresis in a 1.0% agarose gel, stained with ethidium bromide, and visualized under UV transillumination. The sequences and hybridization sites of synthetic oligonucleotide primers are illustrated in figure 1 . All primers were designed on the basis of the complete nt sequence of the CG2 gene described by Su et al. [16] (GenBank accession no. AF030693 for the chloroquine-sensitive HB3/Honduras clone).
DNA sequencing of the CG2 PCR products. The nt sequences were determined by a single-stranded sequencing protocol [17] . Nested or seminested PCR was performed as described above by use of an oligonucleotide primer that was phosphorylated at the 5 end by T4 polynucleotide kinase. The amplification products were purified by glass beads (Jetsorb; Genomed, Research Triangle Park, NC). To generate single-stranded DNA, the purified PCR products were treated with 5 U of l exonuclease (Gibco BRL Life Technologies, Cergy-Pontoise, France) at 37ЊC for 15 min. The reaction mixture was extracted with chloroform-isoamyl alcohol (v/v 24 : 1), and DNA was precipitated by the addition of 0.3 M sodium acetate and cold absolute ethanol. The single-stranded template was used to sequence the amplified product by the dideoxy chain termination reaction.
PCR amplification of surface antigen genes. Because multiple P. falciparum infections are common in Africa [18, 19] , the persistence or reappearance of parasitemia after drug therapy can be ascribed to either recrudescence (i.e., the reappearance of the original parasite populations), a sign of therapeutic failure because of drug resistance or pharmacokinetic factors, or reinfection (i.e., the presence of new parasite populations). To distinguish between recrudescence and reinfection, paired DNA samples from pretreatment and posttherapeutic samples beyond day 4 were compared by PCR analysis of 3 highly polymorphic genes encoding surface antigen circumsporozoite protein (CSP), merozoite surface antigen (MSA)-1, and MSA-2. These surface antigen markers are unlinked.
Specific synthetic oligonucleotides for MSA-1, MSA-2, and CSP genes were designed from published sequences [20] [21] [22] : 5 -ATG-AAGATCATATTCTTTTTATGTTCATTT-3 (MSA-1 forward primer), 5 -TACGTCTAATTCATTTGCACGAATTTTAAG-3 (MSA-1 reverse primer), 5 -ATGAAGGTAATTAAAACATTG-TCTATTATA-3 (MSA-2 forward primer), 5 -TTATATGAATAT-GGCAAAAGATAAAACAAG-3 (MSA-2 reverse primer), 5 -AAATTACAATTCATGATGAGAAAATTAGC-3 (CSP forward primer), and 5 -GATGTGTTCTTTATCTAATTAAGGAA-CAAG-3 (CSP reverse primer). PCR was performed in a 50-mL mixture consisting of genomic DNA, 15 pmol of specific primer pairs, 1.5 mM MgCl 2 , 50 mM KCl, 10 mM Tris-HCl at pH 8.4, 200 mM dNTP, and 1.25 U of Taq DNA polymerase (AppligeneOncor, Illkirch, France). The thermocycle program was as follows: 94ЊC for 2 min for the first cycle and 30 s in subsequent cycles, 50ЊC for 1 min for the first cycle and 30 s in subsequent cycles, and 72ЊC for 1 min (2 min for the CSP gene) for all cycles, for a total of 30 cycles, followed by a 15-min extension step at 72ЊC. The amplified DNA fragments were resolved by electrophoresis in a 1.8% agarose gel, stained with ethidium bromide, and visualized under UV transillumination.
Recrudescence was defined as the presence of identical bands in the pretreatment and posttreatment samples. If multiple bands were observed in the pretreatment sample for a surface antigen gene and one or several of these bands were not amplified in the posttreatment sample, recrudescence as well as the selection of parasite populations was deduced. Reinfection was defined as the presence of different bands in the posttreatment samples.
Determination of drug sensitivity. The phenotype of each isolate was determined by both in vitro and in vivo tests. The isotopic microtest developed by Desjardins et al. [23] was performed on pretreatment isolates without prior adaptation to in vitro culture conditions. Infected erythrocytes were washed 3 times in RPMI 1640 and suspended in complete RPMI 1640 medium consisting of 10% nonimmune human serum, 25 mM HEPES, and 25 mM NaHCO 3 at a hematocrit of 1.5% and an initial parasitemia of 0.1%-0.6%. The suspension was distributed in 96-well culture plates predosed with chloroquine phosphate (final concentrations, 25-1600 nmol/L in triplicate; Sigma, St. Louis) and was incubated at 37ЊC in 5% CO 2 for 18 h. [ 3 H] hypoxanthine (1 mCi/well; Amersham International, Amersham, UK) was added to assess parasite growth. After an additional 24 h of incubation, the plates were frozen to terminate the in vitro assay. The incorporation of [ 3 H] hypoxanthine was quantitated by use of a Wallac 1409 liquid scintillation counter (Pharmacia, Uppsala, Sweden). The IC 50 , defined as the drug concentration corresponding to 50% of the uptake of [ 3 H] hypoxanthine measured in the drug-free control wells, was determined by a nonlinear regression analysis with Prism software (GraphPad, San Diego). The threshold IC 50 for in vitro resistance to chloroquine was estimated to be 1100 nmol/L [24] .
The 14-day test of therapeutic efficacy developed by the World Health Organization (WHO) was used to assess the in vivo sensitivity to chloroquine [25] . The patients from whom the parasites were obtained for this study were treated with the standard dose of chloroquine (25 mg base/kg body weight in 3 divided daily doses) under supervision and were monitored on days 0, 1, 2, 3, 4, 7, and 14. In vivo responses were classified as (1) early treatment failure (ETF), with positive blood smear and signs of severe malaria on days 1, 2, or 3; positive smear (parasite density 1100% day 0 density) and fever on day 2; positive smear and fever on day 3; or positive smear on day 3 (parasite density у25% of pretreatment density); (2) late treatment failure (LTF), with positive smear and signs of either severe malaria or fever between days 4 and 14; or (3) adequate clinical response (ACR), with a negative smear on day 14 (with or without fever) or apyrexia (with positive or negative smear) during the follow-up [25] . In vivo resistance is defined as "the ability of a parasite strain to survive and/or multiply despite the administration and absorption of a drug in doses equal to or higher than those usually recommended but within the limits of tolerance of the subject" [26] .
Results
Because ∼15% of the results of in vitro and in vivo tests are discordant at our study site [24] , 24 isolates with concordant in vitro and in vivo responses were selected for DNA analysis. This preliminary selection of isolates was intended to eliminate several confounding factors, including acquired immunity and poor drug absorption, that may falsely ascribe the cause of therapeutic failure to drug resistance. Thirteen isolates were sensitive to chloroquine in vitro and in vivo (table 1). Only 1 of these patients (no. 3025) was seen after completion of the in vivo test; this patient had a new infection on day 78. Of 11 chloroquine-resistant isolates, 4 were from patients responding with ETF to chloroquine therapy, requiring an alternative treatment on or before day 3. The other patients infected with chloroquine-resistant isolates failed to respond to chloroquine therapy between days 4 and 14 (LTF). The level of chloroquine IC 50 did not differ between ETF and LTF.
The amino acid residues at 12 key positions of the CG2 gene are shown in table 2. Sixteen of 24 isolates displayed pure genotypes; 8 isolates had mixed genotypes, indicating multiple infections. Eight of 11 chloroquine-resistant isolates carried mutant codons at all 12 positions. Each of these isolates displayed a different genotypic pattern of surface antigen genes, suggesting that none of them originated from the same parasite strain that may be circulating at our study site. An analysis of parasites infecting the patients after day 4 and until day 14 after chloroquine treatment showed genetic profiles identical to those of the pretreatment isolates, indicating the persistence of identical parasite populations and thus recrudescence associated with chloroquine resistance.
Two chloroquine-resistant isolates with mixed populations (nos. 1019 and 1020) carried mutations at 10 of the 12 positions implicated in chloroquine resistance. Comparison of the genetic profiles of the surface antigen genes between the pretreatment and recrudescent isolates suggested the initial presence of 2-4 distinct parasite populations in these 2 isolates and reappearance of the same populations, less 1 or 2 populations, as indicated by a decrease in the number of polymorphic bands derived from CSP, MSA-1, or MSA-2 genes (data not shown). These results indicate recrudescence and selection of parasite populations. One chloroquine-resistant isolate (no. 1055) carried 4 mutant codons. However, the patient was aparasitemic on day 7, and the parasites obtained on day 14 showed a genetic profile different from that of day 0, indicating a new infection with different parasite populations. The clinical response of the patient was nonetheless classified as LTF, since WHO criteria do not distinguish between recrudescence and reinfection.
In contrast to the chloroquine-resistant isolates, there was no characteristic CG2 genotype featuring the chloroquine-sensitive isolates. Of 13 chloroquine-sensitive isolates, 6 were mixed populations. The "pure" isolates displaying single codons at all 12 key positions carried 2-9 mutant codons; the mixed isolates carried 7-12 mutant codons. None of the chloroquine-sensitive isolates displayed wild-type codons at all 12 positions, as does the chloroquine-sensitive reference clone HB3/Honduras. In addition, on the basis of the 12 positions implicated in chloroquine resistance, none of the pure or mixed chloroquine-sensitive isolates displayed an identical CG2 pattern.
The pure chloroquine-resistant isolates ( ) were characn = 8 terized by an identical number of repeat units in the k (n = ) and q ( ) repetitive regions (table 3) . Two mixed chlo-14 n = 16 roquine-resistant isolates (1019 and 1020) carried 13 k repeat units and either 14 or 16 (with a second parasite population with 116) q repeat units. The precise number of q repeat units was not determined for isolate 1019 because of an overlapping 
Numbering is based on the complete CG2 gene sequence of the chloroquine-sensitive HB3/Honduras reference clone (GenBank accession no. AF030693) [16] . Amino acid residues at these positions distinguish between laboratoryadapted chloroquine-sensitive (CQS) and chloroquine-resistant (CQR) strains of P. falciparum originating from Africa and Asia. sequencing pattern, but agarose gel electrophoresis of the nested PCR products showed the presence of two bands, one that corresponded to the size of 16 repeat units characteristic of chloroquine-resistant parasites. One pure chloroquine-resistant isolate (1055) with a chloroquine-sensitive CG2 profile at 12 key codons had 12 k and 21 q repeat units. The chloroquinesensitive isolates displayed 11-14 k and 11-21 q repeat units. The numbers of repeat units that characterize the chloroquineresistant parasites, that is, 14 k and 16 q repeat units, were found in 2 mixed chloroquine-sensitive isolates (3019 and 3023). The number of g repeat units ( ) was invariant in all but n = 8 1 isolate studied (no. 1054 with 9 repeat units) and thus was not useful for distinguishing chloroquine-resistant isolates from chloroquine-sensitive parasites. Likewise, the number of repeat units in the J region does not seem to be discriminative. Two pure chloroquine-sensitive parasites (nos. 1009 and 1016) and 3 pure chloroquine-resistant isolates (1005, 1006, and 1023) carried 7 J repeat units. The number of asparagine (Asn) repeats was determined in 9 isolates. Although the number of isolates analyzed was too small to draw a definite conclusion, 11 Asn repeats, characteristic of the chloroquine-resistant strains, were found in 3 of 4 chloroquine-resistant isolates, while there were 7-10 Asn repeats in 5 chloroquine-sensitive isolates.
Discussion
In Yaoundé, Cameroon, our recent clinical studies showed that ∼50% of patients fail to achieve parasite and/or fever clearance after a standard dose of chloroquine [24] . The in vivo data are supported by in vitro monitoring of drug sensitivity of fresh clinical isolates obtained at the same study site [24, 27] . The high rate of therapeutic failure calls for the replacement of chloroquine with other antimalarial drugs (amodiaquine, sulfadoxine-pyrimethamine) in Yaoundé. However, in other African countries, particularly in West Africa, a higher cure rate is still obtained with chloroquine, justifying its use for first-line treatment of uncomplicated malaria [28] . Because chloroquine remains a useful drug that is safe, well tolerated, and affordable for the majority of African patients, the comprehension of the mechanism of chloroquine resistance is of utmost importance for the rational use of the drug.
Our data with fresh clinical isolates largely confirm the findings of Su et al. [16] that the CG2 gene is implicated in the development of chloroquine resistance in P. falciparum. Our results also demonstrate the coexistence of multiple parasite populations with several alternative CG2 codons in persons who may or may not clear parasitemia after chloroquine therapy. Both point mutations at 12 key positions and size polymorphism of repeat regions in the CG2 gene seem to play a role in determining the drug sensitivity/resistance phenotype. A unique "Dd2-type" of CG2 profile was associated with chloroquine resistance, whereas various profiles were observed in the chloroquine-sensitive isolates. Except for 1 chloroquine-sensitive multiple infection with all 12 mutant codons (isolate 3023), all pure parasite populations with 12 mutant codons were associated with elevated IC 50 levels for chloroquine and with therapeutic failure within 14 days.
The Dd2-type chloroquine-resistant CG2 profile was observed in Cameroonian clinical isolates analyzed in the present study and in laboratory-adapted strains and clones originating -16  1055  12  8  --21  3028  14  8  --16  171  14  8  --16  CQ3  14  8  --16  CQ9  14  8  --16 NOTE. Dashes (-), not done. a Some polyclonal isolates presented mixed patterns of repeat regions. In the k and J repeat regions, the no. of mixed repeat units was determined from the overlapping pattern seen by DNA sequencing. In the q repeat region, the no. of mixed repeat units was estimated on a 1.8% agarose gel by comparison of the band sizes with those of isolates presenting wth a single band.
from various African and Asian countries [16] . The chloroquine-resistant 7G8/Brazil reference clone exhibited a distinct CG2 profile, attributed by Su et al. [16] to a series of independent genetic changes leading to a chloroquine-resistant phenotype in South America. Although none of the chloroquinesensitive isolates in our series presented an identical CG2 profile, the distribution of mutations in the 12 key positions does not seem to be at random. Thus, positions 973, 2086, 2179, and 2181 were more frequently occupied by mutant codons than were other residues in the pure chloroquine-sensitive isolates. By contrast, the amino acid residues at both ends of the CG2 gene tended to be of wild-type codon in the pure chloroquinesensitive parasites. Although a stepwise, and possibly orderly, accumulation of mutations at 12 key sites may be hypothesized, the occurrence of mutations in clusters needs confirmation in a larger sample of naturally occurring parasites. Nevertheless, these observations seem to suggest that the genetic mechanism of chloroquine resistance involves a slow cumulative process in which the gradual acquisition of 12 point mutations at specific sites, probably selected under drug pressure, is required for an abrupt shift in the phenotype from sensitivity to resistance. Our data on fresh clinical isolates, along with those of Su et al. [16] on laboratory-adapted strains, further suggest that a partial accumulation of point mutations (i.e., up to 11 mutant codons) is insufficient to express the resistant phenotype. Chloroquine resistance may thus be an "all or none" phenomenon that requires all 12 point mutations in the CG2 gene. However, because the wild-type versus mutant codons in these positions were based on comparison of sequences of the chloroquine-sensitive HB3/Honduras clone and the chloroquine-resistant Dd2/Indochina clone, and South American clones seem to undergo distinct mutations [16] , the wild-type codons at these 12 key positions in African parasites are yet to be confirmed. The polymorphic repeat regions also seem to play an important but probably less determinant role. Although the g repeat region exhibited a limited polymorphism that was obviously unrelated to chloroquine resistance, both k and q repeat regions were well correlated with chloroquine resistance, at least in pure parasite populations, in this study. The k repeat region is characterized by the presence of 14 repeat units in the resistant parasites, and р13 (11-13) were found in the present study and in that of Su et al. [16] . As for the q repeat region, the presence of 16 repeat units characterizes the chloroquine-resistant parasites, whereas there may be 10-32, but not 16, repeat units in the chloroquine-sensitive parasites. However, further analysis of the q repeat region in 75 Cameroonian clinical isolates showed that among 40 isolates with 16 q repeat units, 10 were chloroquine-sensitive in vitro and 30 were chloroquineresistant [29] . Moreover, 7 of 35 isolates with either р15 or у17 q repeat units were resistant in vitro to chloroquine. Thus, the number of q repeat units is not the sole determinant for chloroquine resistance. So far, it is not clear whether amplification, unequal recombination, or another mechanism is responsible for the size polymorphism and whether the precise length of the polymorphic regions is required for the structural configuration that allows the functionality of the expression product of the CG2 gene.
Our results showed, on the basis of the CG2 sequence, that several isolates were discordant between the genotype and phenotype. One isolate (no. 1055) had an elevated IC 50 , and the patient cleared asexual parasites on day 7 but was parasitemic on day 14 with a new infection. The CG2 genotype of the pretreatment isolate predicted a chloroquine-sensitive profile. In this patient, the therapeutic failure was not due to drug resistance, because parasite clearance was followed by the appearance of a new population of parasites. An effective acquired immune response may explain the clearance of parasites characterized to be resistant in vitro. Discordant results were also observed in multiple infections. Of the 11 chloroquine-resistant isolates, 2 were multiple infections with у2 distinct parasite populations. The interpretation of phenotype and genotype is not clear-cut in multiple infections, because the elevated IC 50 , in vivo failure to clear the parasites, and in vivo selection of parasite populations result from the dynamic interaction of various factors that intervene in the host-parasite relationship, including acquired immune system, pharmacokinetics, phar-macodynamics, and evolution and domination of different parasite populations at different moments of the parasite life cycle in the human host.
Likewise, it is not clear why a chloroquine-sensitive multiple infection, with what may be interpreted as the presence of у1 parasite population characterized by 12 mutant codons, 14 k repeat units, and 16 q repeat regions (isolate 3023), did not persist or reappear in the patient within 14 days after chloroquine therapy. We hypothesize that this particular isolate may have been composed of several populations with several different mutant codons and that there may have been no single population with all 12 mutant codons. Although acquired immunity may be incriminated in the elimination of the mutant parasite population(s), there is no biologic proof that quantitates the effectiveness of the immune response in individual patients. Among laboratory-adapted P. falciparum strains, the chloroquine-sensitive 106/1 strain from Sudan also exhibited the typical CG2 profile for chloroquine resistance [16] . Although genetic changes in other genes may be implicated in these parasites, at present the cause of the discordant cases remains unknown.
These discordant results suggest that there is still no unequivocal explanation of the mechanism of chloroquine resistance. The expression product of the CG2 gene was localized to the parasitophorous space and within the digestive vacuole, but its function is still undetermined [16] . The sequence of the CG2 gene is not homologous to any other known gene, which renders the search for its function more difficult. Although it has been proposed that, based on the presence of a 5 amino acidconsensus motif, the expression product of the CG2 gene may be the membrane-associated Na ϩ /H ϩ antiporter that regulates intracellular pH and transports chloroquine into the parasites, biochemical studies on the CG2 gene product have not been done to demonstrate these functional properties [9, 30, 31] .
In conclusion, our data suggest a strong association between the chloroquine sensitivity/resistance phenotype and CG2 genotype in Cameroonian clinical isolates and confirm that CG2 may be a promising candidate gene for chloroquine resistance. Further studies are clearly needed to define the functional role of the expression product of the gene.
